Literature DB >> 21109375

Erythropoietin in neonatal brain protection: the past, the present and the future.

Abdullah Kumral1, Funda Tüzün, Meryem Gülfer Oner, Sermin Genç, Nuray Duman, Hasan Ozkan.   

Abstract

Over the last decade, neuroprotective effects of erythropoietin (Epo) and its underlying mechanisms in terms of signal transduction pathways have been defined and there is a growing interest in the potential therapeutic use of Epo for neuroprotection. Several mechanisms by which Epo provides neuroprotection are recognized. In this review, we focused on the neuroprotective mechanisms of Epo and provide a short overview on both experimental and clinical studies, testing Epo as a neuroprotective agent in the neonatal brain injury, and the safety concerns with the clinical use of Epo treatment in neonates.
Copyright © 2010 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109375     DOI: 10.1016/j.braindev.2010.10.014

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  18 in total

1.  High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.

Authors:  Andrei M Beliaev
Journal:  Blood Transfus       Date:  2013-03-19       Impact factor: 3.443

Review 2.  Perinatal stroke: a case-based review.

Authors:  Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2011-06-25       Impact factor: 3.183

3.  Erythropoietin attenuates advanced glycation endproducts-induced toxicity of Schwann cells in vitro.

Authors:  Ting Yu; Lei Li; Tianhua Chen; Zhen Liu; Huaxiang Liu; Zhenzhong Li
Journal:  Neurochem Res       Date:  2015-01-14       Impact factor: 3.996

Review 4.  Early erythropoiesis-stimulating agents in preterm or low birth weight infants.

Authors:  Arne Ohlsson; Sanjay M Aher
Journal:  Cochrane Database Syst Rev       Date:  2017-11-16

Review 5.  Translating cell survival and cell longevity into treatment strategies with SIRT1.

Authors:  K Maiese; Z Z Chong; Yan Chen Shang; S Wang
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

Review 6.  SIRT1: new avenues of discovery for disorders of oxidative stress.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Expert Opin Ther Targets       Date:  2012-01-10       Impact factor: 6.902

7.  Neuroprotective Effect of Erythropoietin on Phenylhydrazine-Induced Hemolytic Hyperbilirubinemia in Neonatal Rats.

Authors:  Asli Memisoglu; Meltem Kolgazi; Akan Yaman; Elif Bahadir; Serap Sirvanci; Berrak Ç Yeğen; Eren Ozek
Journal:  Neurochem Res       Date:  2016-12-19       Impact factor: 3.996

8.  Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

9.  Long-term moderate dose exogenous erythropoietin treatment protects from intermittent hypoxia-induced spatial learning deficits and hippocampal oxidative stress in young rats.

Authors:  Jobran M Al-Qahtani; Basel A Abdel-Wahab; Samy M Abd El-Aziz
Journal:  Neurochem Res       Date:  2013-11-20       Impact factor: 3.996

10.  PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.